@article{618de1b35dde41239db03a4e00e0e002,
title = "Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma",
abstract = "Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly understood. Recent data suggest some of these molecular features may be biomarkers of response to recently introduced biologically-targeted therapies, namely endocrine therapy and MEK inhibitors. We utilize a cohort of 63 pathologically-confirmed LGSOC cases with whole exome sequencing and hormone receptor expression data to investigate these relationships. LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progesterone receptor (PR) expression intensity. 60% and 37% of cases demonstrated micropapillary and macropapillary patterns of stromal invasion, respectively. 63% of cases demonstrated desmoplasia, which was significantly associated with advanced disease stage and visible residual disease after cytoreductive surgery. MAPK-mutant cases (KRAS, BRAF, NRAS) more frequently demonstrated macropapillary stromal invasion, while Chr1p loss was associated with desmoplasia and low PR expression. Presence of micropapillary stromal invasion and low PR expression were associated with significantly poorer survival after accounting for stage and residual disease status. Together, these data identify novel relationships between histopathological features and molecularly-defined subgroups in LGSOC.",
author = "Hollis, {Robert L.} and Thomson, {John P.} and {van Baal}, Juliette and Narthana Ilenkovan and Michael Churchman and {van de Vijver}, Koen and Frederike Dijk and Meynert, {Alison M.} and Clare Bartos and Tzyvia Rye and Ian Croy and Patricia Diana and {van Gent}, Mignon and Helen Creedon and Rachel Nirsimloo and Christianne Lok and Charlie Gourley and Herrington, {C. Simon}",
note = "Funding Information: RLH was supported by Target Ovarian Cancer (Edinburgh-CG19) and by an IGC Langmuir Talent Fellowship. This work was funded in part by a HANARTH Foundation grant. We extend our thanks to The Nicola Murray Foundation for their generous support of The Nicola Murray Centre for Ovarian Cancer Research. JT and CB were supported by core funding from the CRUK Scotland Centre. AMM was supported by core funding awarded to the MRC Human Genetics Unit. We are grateful to the NHS Lothian Department of Pathology, Edinburgh Experimental Cancer Medicine Centre, the Edinburgh Ovarian Cancer Database and the NRS Lothian Human Annotated Bioresource for their ongoing support. We also thank the NKI- AVL Molecular Pathology & Biobanking Core Facility (CFMPB). Funding Information: RLH was supported by Target Ovarian Cancer (Edinburgh-CG19) and by an IGC Langmuir Talent Fellowship. This work was funded in part by a HANARTH Foundation grant. We extend our thanks to The Nicola Murray Foundation for their generous support of The Nicola Murray Centre for Ovarian Cancer Research. JT and CB were supported by core funding from the CRUK Scotland Centre. AMM was supported by core funding awarded to the MRC Human Genetics Unit. We are grateful to the NHS Lothian Department of Pathology, Edinburgh Experimental Cancer Medicine Centre, the Edinburgh Ovarian Cancer Database and the NRS Lothian Human Annotated Bioresource for their ongoing support. We also thank the NKI- AVL Molecular Pathology & Biobanking Core Facility (CFMPB). Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = dec,
day = "1",
doi = "https://doi.org/10.1038/s41598-023-34627-5",
language = "English",
volume = "13",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Springer Nature",
number = "1",
}